Replies to post #149 on Sio Gene Therapies Inc (fka SIOX)

[georgejjl]

Cohort 3 of the AXO-Lenti-PD trial is scheduled to start around the end of calendar 2021 or early 2022. Cohort 3 will be 3 times the concentration as the dose given to Cohort 2.

Cohort 2 (n=2 evaluable patients): Positive 6-month data
demonstrating 21-point mean improvement from baseline in
UPDRS III “OFF” score

https://investors.siogtx.com/static-files/53b38274-3d1f-4d98-a157-93e04b94646a

Watch the video below regarding and ProSavin trial from Oxford BioMedica.

Good luck and GOD bless,